G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
98 hedge funds and large institutions have $98.2M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 21 increasing their positions, 33 reducing their positions, and 39 closing their positions.
188% more call options, than puts
Call options by funds: $463K | Put options by funds: $161K
15% less funds holding
Funds holding: 115 → 98 (-17)
36% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 39
36% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 33
47% less capital invested
Capital invested by funds: $184M → $98.2M (-$86M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$9.95M |
| 2 |
Millennium Management
New York
|
+$3.34M |
| 3 |
Renaissance Technologies
New York
|
+$2.57M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.25M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19.6M |
| 2 |
BlackRock
New York
|
-$10.7M |
| 3 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$4.12M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
-$3.13M |
| 5 |
Rafferty Asset Management
New York
|
-$1.95M |
GTHX Hedge Fund Activity: Q2 2022 in Review
98 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2022, worth a combined $98.2M — down 47% from $184M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of GTHX and 25 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 21 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $9.95M. The largest seller was State Street, cutting an estimated $19.6M.
- 98 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2022, down from 115 in Q1 2022.
- Funds reported $98.2M of G1 Therapeutics, Inc. Common Stock stock for Q2 2022, down 47% quarter-over-quarter.
- 25 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2022 and 39 closed out, a net change of -14 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2022 was Woodline Partners, an estimated $9.95M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2022 was State Street, an estimated $19.6M sold.
Based on aggregated 13F filings for Q2 2022.